

**To:** CN=Robert W Baker/OU=AM/O=LLY@Lilly; CN=Michael E Bandick/OU=AM/O=LLY@Lilly;  
CN=Mauricio F Tohen/OU=AM/O=LLY@Lilly  
**Date:** 09/22/2003 12:04:19 PM  
**From:** CN=Virginia Stauffer/OU=AM/O=LLY  
**Subject:** Re: Notification of Class Labeling for Atypical Antipsychotics

Rahsmi did communicate with Dan Casey regarding the label change. Thought you would be interested in his not suprising response.

Ginny

**Rashmi S Yadav**

**Marya**

09/22/2003 10:43 AM

To: Bryan Johnstone/AM/LLY@Lilly, Virginia Stauffer/AM/LLY@Lilly, Komathi Stem/AM/LLY@Lilly  
cc:  
Subject: Re: Notification of Class Labeling for Atypical Antipsychotics

FYI -

----- Forwarded by Rashmi S Yadav Marya/AM/LLY on 09/22/2003 08:42 AM -----

**Daniel Casey**

<caseyd@ohsu.edu>

09/19/2003 04:37 PM

To: YADAV\_MARYA\_RASHMI\_S@Lilly.com  
cc:  
Subject: Re: Notification of Class Labeling for Atypical Antipsychotics

R

Thank you.

It is too bad that the FDA got it wrong. I am sure that there is a differential effect within the class.

Page: 1 of 2

DEC